Concarlo Therapeutics
Brooklyn
About Concarlo Therapeutics
Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics to target drug-resistant cancers. Concarlo’s vision is to create a world of possibility and time, where cancer is a treatable, manageable, and survivable condition. Concarlo is developing therapies to drug p27, the natural inhibitor of CDK4/CDK6 and CDK2. The company is harnessing decades of research to target a unique cellular pathway to kill – not just stop – the growth of tumor cells. Concarlo is leveraging its deep understanding of this pathway to develop new treatments for a wide range of advanced and drug-resistant cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $7.0M
- Last round: Series Unknown (Jan 2020)
- Website: concarlo.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Diagnostics, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/concarlo-therapeutics-10602 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.